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Abstract  
BACKGROUND: Beta Thalassemia is the most common chronic hemolytic anemia in Egypt 
(85.1%) with an estimated carrier rate of 9-10.2%. Injury to the liver, whether acute or chronic, 
eventually results in an increase in serum concentrations of Alanine transaminase (ALT) and 
Aspartate transaminase (AST). 
AIM: Evaluating the potentiating effect of iron overload & viral hepatitis infection on the liver 
enzymes. 
PATIENTS AND METHODS: Eighty (80) thalassemia major patients were studied with respect to 
liver enzymes, ferritin, transferrin saturation, HBsAg, anti-HCV antibody and HCV-PCR for anti-HCV 
positive patients.  
RESULTS: Fifty % of the patients were anti-HCV positive and 55% of them were HCV-PCR 
positive. Patients with elevated ALT and AST levels had significantly higher mean serum ferritin 
than those with normal levels. Anti-HCV positive patients had higher mean serum ferritin, serum 
ALT, AST and GGT levels and higher age and duration of blood transfusion than the negative 
group. HCV-PCR positive patients had higher mean serum ferritin and serum ALT and also higher 
age and duration of blood transfusion than the negative group.  
CONCLUSION: Iron overload is a main leading cause of elevated liver enzymes, and presence of 
HCV infection is significantly related to the increased iron overload. 
 
 
 
 
 
 
Introduction 
 
Thalassemia is among the most common 
genetic disorders, and nearly 7% of the world 
population carry a hemoglobinopathy [1]. The burden 
of this disorder in many regions is of such a 
magnitude that it represents a major public health 
concern [2]. Transfusion therapy which is the main 
way of treatment allows for normal growth and 
suppresses ineffective erythropoiesis [3]. Iron 
overload is often inevitable, especially when iron 
chelating agents are not used properly [4]. Even in the 
absence of transfusion, the accelerated rate of 
erythropoiesis enhances dietary iron absorption from 
the gut, resulting in a chronic state of iron overload [5]. 
As patients with thalassemia commonly receive 
transfusions, they are exposed to transfusion-
associated infections, where hepatitis B and hepatitis 
C are the most common infections detected [6]. 
Although the risk of post-transfusion hepatitis C virus 
(HCV) infection dropped significantly after the national 
screening of blood in 1993, more than 20% of children 
who were multitransfused after that date were HCV-
RNA positive [7]. In Egypt, prevalence rate of HCV 
antibodies seropositivity in thalassemic children at 
2011was 51.7% [8] while in the study of El-Faramawy 
et al., (2012) [9], a prevalence of 48 % was reported. 
Iron overload and hepatitis-C virus (HCV) 
infection, have been implicated in the evolution of liver 
disease, in patients with transfusion-dependent beta-
thalassaemia major (BTM). The impact of these 
factors in late stages of liver disease with BTM, has 
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not been extensively studied yet.  
Interrelationship between iron overload, HCV 
infection and liver injury is still controversial. 
Multicenter
 
cross-sectional studies have reported that 
the development and
 
the severity of liver injury are 
strongly related to the extent
 
of liver iron overload and 
to the presence of chronic HCV infection [10, 11]. 
Long-term observation of thalassemics who 
had undergone bone
 
marrow transplantation showed 
that severe iron overload and
 
chronic HCV infection 
were independent risk factors for liver
 
injury [12]. 
Hepatitis virus C infection is the main risk factor for 
liver injury in transfusion-dependent thalassemics [13]. 
Dimitrios et al (2013) [14] on the other hand 
suggested that in the late stages of liver disease in 
BTM patients, iron overload may be the critical 
determinant, since fibrosis is related to the minimal 
haemosiderosis, independently of HCV history. Injury 
to the liver, whether acute or chronic, eventually 
results in an increase in serum concentrations of 
Alanine transaminase (ALT) and Aspartate 
transaminase (AST) [15].  
We aimed in this study to determine the 
relationship between liver enzymes with serum iron 
status and HCV infection in thalassemic patients and 
to throw light on the percentage of HBV and HCV in 
the studied patients.  
 
 
Subjects and Methods  
 
This cross sectional study was conducted on 
80 patients with beta-thalassemia major. They were 
recruited from the Hematology Clinic in New Children 
Hospital, Cairo University, their ages ranged from 5 to 
18 years with a mean age of 11.09 ± 4.156 years. 
Forty three (53.7%) of them were males and thirty 
seven (46.3%) were females. An informed parental 
consent was obtained from every case before the 
study. Inclusion criteria of patients were; age ranging 
from 5 to 18 years, undergoing regular blood 
transfusion and had clinical follow up for at least 24 
months before study. Any child with a history of liver 
affection (congenital, autoimmune hepatitis, hereditary 
hemochromatosis) was excluded from the study. All 
subjects underwent the following: I - Complete history 
taking: A questionnaire was planned to fulfil: 1) 
Demographic data: name, age, sex, socioeconomic 
classes, consanguinity and positive family history of 
thalassemia. 2) Medical history: age of onset duration, 
age of start of blood transfusion, and its frequency, 
history of splenectomy and history of liver affection. 3) 
Regimen of management: type of therapy received, 
including chelation therapy (dose, age of start, 
complications and compliance). II - Complete physical 
and clinical examination: Thorough clinical 
examination with particular emphasis on presence of 
pallor, jaundice, and signs of thalassemic features. 
Abdominal examination for hepatosplenomegally. III - 
Laboratory investigations: Blood was collected by 
venipuncture and was allowed to clot naturally and 
completely. The serum was separated from the clot; 
hemolysis of the RBC was avoided. Care was taken to 
ensure that the serum samples are not contaminated. 
Collection tubes were iron free. Serum stored in 
Stopper tubes at 2-8°C till time laboratory 
investigations which included: 1) Iron status as 
indicated by serum ferritin level and transferrin 
saturation. 2) Liver functions as indicated by serum 
level of Alanine transaminase (ALT), Aspartate 
transaminase (AST) and Gamma-glutamyl 
transpeptidase (GGT). 3) Detection of hepatitis viral 
infection by Hepatitis B surface antigen (HBsAg), Anti-
hepatitis C virus (anti-HCV) antibody and RNA-PCR 
testing for HCV positive patients.  
 
Serum ferritin level 
Diametra, CA06034, Italy, Direct 
immunoenzymatic determination of ferritin in human 
serum or plasma [16]. Expected values: Normal 
range: male 6-180 ng/L female 20-400 ng/L. 
Transferrin saturation: It is the ratio of serum 
iron and total iron-binding capacity, multiplied by 100 
(normal range: 15-50%). Iron and Total Iron Binding 
Capacity (TIBC) were measured by CA0370, USA, 
Quantitative colorimetric determination of  
iron and unsaturated iron-binding capacity in serum 
[17]. Serum iron expected values in children are 40-
120 g/dL. TIBC expected values in children are 250-
400 g/dL. Alanine transaminase (ALT): Stanbio 
ALT/GPT (UV-Rate), CA0930, USA, Quantitative 
determination of ALT/GPT in serum [18]. Expected 
values: Normal range: 0-38 U/L at 37°C Aspartate 
transaminase (AST): Stanbio AST/GOT (UV-Rate), 
CA0920, USA, Quantitative determination of 
AST/GOT in serum [19]. Normal range: 0-40 U/L at 
37°C. Gamma-glutamyl transpeptidase [20]
 
(GGT): 
Centronic GmbH, CA85456, Germany, Enzymatic 
colorimetric test for the determination of L-γ-
glutamyltransferase (Szasz method) in serum and 
plasma. Expected values: normal range: male 11-49 
IU/L, female 7-32 IU/L. Hepatitis B surface antigen 
(HBsAg): Prechek Bio, Inc. CA92806, USA, 
Diagnostic kit for hepatitis B virus surface antigen 
(ELISA), one-step incubation, double-antibody 
Sandwich principale [21]. Anti-hepatitis C virus (anti-
HCV) antibody: Prechek Bio, Inc. CA92806, USA, 
Diagnostic kit for antibody to hepatitis C virus (ELISA), 
two-step incubation, indirect principale [22]. HCV-
PCR: Positive cases for HCV antibodies were 
subjected to PCR for HCV-RNA reverse transcriptase 
PCR (RT-PCR). Qualitative estimation of HCV-RNA in 
serum was detected by nested RT-PCR assay. 
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Statistical analysis 
Data were analyzed using the statistical 
package for social science (SPSS). Computer 
software package SPSS 15.0 was used in the 
analysis .For quantitative variables, mean, standard 
deviation, minimum, and maximum (as measures of 
variability) were presented. Frequency and 
percentages were presented for qualitative variable. 
ANOVA, Independent T, Mann-Whitney and Kruskal 
Wallis tests were used to estimate differences in 
quantitative variables. Chi-square and test was used 
to estimate differences in qualitative variables. 
Spearman’s rank correlation test was used to 
determine the relationship between different numerical 
variables. For all tests, probability values (P) of less 
than 0.05 were regarded as statistically significant. 
 
 
Results 
 
This study included 80 patients with beta 
thalassemia major; their age ranged from 4-18 years 
with a mean age of 11.09 ± 4.156 years. They were 
43 males (53.75%) and 37 (46.25%) females. Positive 
consanguinity was present in 43 (53.75%) patients 
and 35 (43.75%) had positive family history of other 
members affected. Thirty two patients (40%) suffered 
from jaundice and 34 (42.5%) had thalassemic 
features. All patients were on regular blood 
transfusion with a mean frequency of 12.94 ± 4.31 
times per year. The age of onset of blood transfusion 
ranged from 2-12 month with a mean of 6.84 ± 2.9 
months. There was a significant decrease in the 
frequency of blood transfusion per year in patients 
who underwent splenectomy (n = 55), compared to 
the pre-splenectomy period (P = 0.034). 
Table 1: Comparison between deferiprone and deferoxamine 
as regards the biochemical parameters 
Parameter Deferiprone 
(mean ± SD) 
Deferoxamine 
(mean ± SD) 
p-value 
Serum ALT U/L 95.21 ± 74.070 158.44 ± 135.207 0.013* 
Serum AST U/L 59.04 ± 95.98 81.72 ± 98.19 0.39 
Serum GGT IU/L 23.83 ± 52.24 25.25 ± 22.97 0.91 
Serum ferritin ug/L 805.61 ± 424.38 904.61 ± 374.32 0.38 
TSAT % 76.46 ± 39.25 72.44 ± 27.03 0.68 
 *P value is significant if < 0.05  
 
Seventy five patients were on regular 
chelation therapy; 78.7 % of these patients were 
compliant with chelators, 5 patients only were not on 
any chelation therapy because of the complication of 
oral chelators or refusal of injections. All the 
thalassemic patients included in the study were on 
folic acid, calcium and vitamin D therapy. Only 47.5 % 
of the patients received L-carnitine. No significant 
difference was noted in the mean level of ferritin, 
transferritin saturation or number of blood transfusion 
per year between patients on L-carnitine and those 
who did not receive it (data not shown).  
In comparison of biochemical parameters in 
the two types of iron chelators, only serum ALT 
showed a significant decrease in patients on 
deferiprone therapy (p=0.013) (Table 1). 
None of our patients was positive for HBSAg; 
however 40 (50%) patients were anti-HCV positive, 
where only 22 of them (55%) were PCR positive 
which contributes to 27.5% of the 80 patients included 
in the study. 
According to the level of each biochemical 
parameter the patients were divided into 2 groups, 
one with normal level and the other with high level. 
The percentage of patients with elevated levels of ALT 
and parameters of iron status are very high (Fig. 1). 
 
Figure 1: Percentage of patients with normal and elevated levels of 
biochemical parameters 
 
Mean serum ferritin level was significantly 
higher in patients with either elevated ALT level or 
elevated AST level as compared to those with normal 
ALT or AST levels (p=0.007 and 0.004 respectively) 
(Table 2). 
Table 2: The mean ferritin level as regard to ALT and AST level 
  Ferritin (ng/L) 
Mean ± SD 
P value 
Pts.with normal ALT level (N=24) 633.96 ± 360.1  
0.007* Pts. with high ALT level (N=56) 903.21 ± 412.47 
Pts. with normal AST level (N=42) 698.74 ± 371.8  
0.004* Pts. with high AST level (N=38) 959.16 ± 420.33 
*P value is significant if < 0.05  
 
A significant high number of patients with +ve 
anti –HCV antibody had an above normal level of 
either ALT or AST (Table 3).  
Table 3: Comparison between normal and high ALT level as 
regard to the number of patients with positive infection of HCV  
 Anti-HCV 
P value +ve (40) -ve (40) 
Pts.with normal ALT level (N=24) 7 17 
0.027* 
Pts. with high ALT level (N=56) 33 23 
Pts. with normal AST level (N=42) 13 29 0.001* 
Pts. with high AST level (N=38) 27 11  
*P value is significant if < 0.05  
 
In addition, by comparing the mean level of 
liver enzymes (ALT, AST and GGT), ferritin and 
transferritin saturation in patients with +ve Anti-HCV to 
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those with –ve Anti-HCV, there were significantly 
higher levels of all parameters (except for TSAT%) in 
patients with +ve Anti-HCV. Serum ALT and ferritin on 
the other hand are the only parameters that showed 
significantly higher levels in the +ve HCV-PCR 
patients as compared to those with –ve HCV-PCR (p= 
0.007and 0.001 respectively (Table 4).  
Table 4: The mean ± SD of liver enzymes, ferritin and 
transferritin saturation regarding Anti-HCV and HCV-PCR 
results  
 
Anti-HCV 
(N=80) 
HCV-PCR 
(N=40) 
+ve          - ve  p-value  +ve            - ve p-value 
ALT (U/L) 
Mean 
 ± SD 
 
137.2       80.2 
±106.8     ±68.8 
0.006* 
 
153.86         91.47 
 ±115.89     ±78.57 
0.007* 
AST (U/L) 
 Mean ± SD 
 
87            38.3 
±123.4      ±36.2 
0.019* 
 
 82.00         55.36 
 ±86.89       ±95.77 
0.259 
GGT (U/L) 
 Mean ± SD 
 
 34.3        13.17 
±62.25      ±8.5 
0.037* 
 
 30.15        21.31 
 ±30.44      ±49.96 
0.44 
Ferritin (μg /L) 
Mean ± SD 
 
  
933.82    711.05 
±443.55  ±354.19 
0.015* 
  
1060.46     732.16 
 ±460.32   ±360.04 
0.001* 
Transferrin 
Saturation % 
Mean ± SD 
 
  
 68.0         80.45 
±22.77     ±44.82 
 
0.122 
  
  68.64        75.47 
 ±23.43      ±40.33 
0.458 
*P value is significant if < 0.05  
  
The mean level of ALT and GGT in patients 
with high level of ferritin (> 320 g/l) are significantly 
higher as compared to those with ferritin level (< 320 
g/l), (p = 0.04 and 0.05 respectively) (Table 5). No 
such difference was found on the other hand, when 
comparing the mean levels of liver enzymes (ALT, 
AST, GGT), in patients with high level of transferritin 
saturation to those with normal level.  
Table 5: The mean ± SD of ALT, AST and GGT according to 
Ferrintin level  
Parameter Ferrintin level (>320 ug/l) 
n=63 
Ferrintin level (<320 ug/l) 
n=17 
P 
ALT (U/L) 
Mean ± SD 
 
118.27 ± 97.03 
 
72.88 ± 72.77 
0.04
*
 
AST (U/L)  
Mean ± SD 
 
59.58 ± 63.66 
 
74.18 ± 165.55 
N.S 
GGT (IU/L) 
Mean ± SD 
 
26.53 ± 50.66 
 
13.39 ± 9.56 
0.05
*
 
*P value is significant if < 0.05  
 
Serum ferritin level correlated positively with 
GGT level (r = 0.23 and p = 0.006) as shown in Fig. 2, 
but not with ALT or AST levels. 
 
Figure 2: Correlation between serum ferritin and GGT level 
Serum ALT level correlated positively with the 
age of the patients (r = 0.3 and p = 0.01), and with the 
duration of blood transfusion (r = 0.3 and p = 0.01). 
No correlation on the other hand was found between 
transferritin saturation and either age of patients or 
duration of blood transfusion. 
 
 
Discussion 
 
The aim of this study was to evaluate the 
potentiating effect of iron overload and viral hepatitis 
infection on liver enzymes as a marker for hepatic 
injury in Egyptian children with thalassemia major, and 
to throw light on the percentage of HBV and HCV 
infection in studied thalassemic children. 
This study was conducted on 80 thalassemic 
patients, 55 of them underwent splenectomy which 
resulted in a significant decrease in the mean number 
of times of blood transfusion per year compared to the 
pre-splenectomy period (p = 0.034). These results are 
in accordance with the study of Al-Salem 
and Nasserulla (2002) [23] which showed that in 
children who had total splenectomy, their 
postsplenectomy transfusion requirements decreased 
from a preoperative mean of 17.8 transfusions per 
year to a postoperative mean of 10 transfusions per 
year. In addition, Morsy et al., (2008) [24] revealed 
that the total amount of blood given over a whole year 
was significantly lower in the splenectomized group of 
their patients. 
Our results showed that only 7 patients 
(12.2%) had complications due to deferiprone therapy 
in the form of elevated liver enzymes, arthralgia and 
GIT upsets in the form of abdominal pain, while there 
were no reported significant complications from 
deferoxamine. Same observation was noted in other 
previous studies [25, 26].  
In the present study no difference was noted 
in the efficacy of the two iron chelators as denoted by 
absence of significant differences in serum levels of 
iron parameter between patients receiving deferiprone 
and those receiving deferoxamine. Previous 
comparative studies have shown that at comparable 
doses the efficacy of deferiprone( DFP) in removing 
body iron is similar to that of desferoxamine (DFO) 
and deferiprone seems to be a valuable alternative 
and an effective iron chelator for patients unable or 
unwilling to use deferoxamine [25, 27]. El-Alfy et al., 
(2010) [28], on the other hand revealed that 
deferiprone use was associated with a high significant 
decline in mean serum ferritin level (P < 0.0005). 
Our results showed higher levels of liver 
enzymes in patients treated by deferoxamine but the 
difference was significant only in serum ALT level. 
 
r =0.23     P = 0.006 
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Thalassemia major patients receiving L-
carnitine therapy need significantly less blood 
transfusions per year [29], and there is an 
improvement in their serum ferritin level [30]. L-
carnitine intake by 47.5% of our thalassemic patients 
had no significant effect on their serum ferritin level, 
transferrin saturation or number of blood transfusions 
per year. This could be due to inadequate intake of L- 
carnitine due to irregularity of receiving it or the 
duration of intake was too short to improve the 
condition. 
The mean serum ferritin level was significantly 
higher in thalassemic patients with elevated ALT or 
elevated AST compared to those patients with normal 
levels (p = 0.007 and 0.004 respectively). 
Furthermore, the mean ALT and GGT levels were 
significantly higher in patients with high ferritin level as 
compared to those of normal ferritin level. These 
findings are in agreement with other previous studies 
[3, 31] who reported that abnormal ALT level is 
associated with higher ferritin and transferring 
saturation. 
Fortunately none of the patients included in 
this study was HBSAg positive. Absence of positive 
HBSAg among studied thalassemic patients was also 
reported by Amli et al., (2008) [3] and Omar et al., 
(2011) [8]. Hepatitis B virus infection occurred in only 
one patient (2%) out of 50 thalassemics in the study of 
El Gawhary et al., (2009) [32], While in the study of El-
Faramawy et al., (2012) [9] 12% of patients were 
infected with HBV. The decrease in the prevalence of 
hepatitis B infection in this study and some other 
studies reflects the efficacy of the vaccination program 
and effective screening of blood and blood products 
for these patients. Although the prevalence of HBsAg 
among Egyptian polytransfused children decreased, it 
is still high in some studies in different geographical 
areas, and this could be attributed to the high infection 
rates among those children despite vaccination 
against HBV, as they might not have responded 
adequately to vaccination or may not be fully 
vaccinated. 
Fifty percent of our studied patients were anti-
HCV positive and only 55% of these positive patients 
were HCV-PCR positive which contribute to 27.5% of 
the 80 patients included in the study. 
Similar results were reported in the study of 
Omar et al (2011) [8], as 51.7% of their patients were 
HCV antibodies positive and only 25% of the studied 
patients were positive for HCV infection by PCR. In 
addition, the study of Din et al, (2014) [33] revealed 
that 49% of their thalassemic patients were positive 
for anti-HCV antibodies. 
Lower percentage of thalassemic patients 
with HCV positive antibodies (40.5%) were reported in 
the study of Masour et al., (2012) [34]. Furthermore, 
Hussein (2014) [35], reported that 48 of 200 (24%) of 
multi-transfused Egyptian children with thalassemia 
were positive for HCV antibodies. 
Higher results were obtained in the study of 
Elalfy et al (2010) [28] who revealed that 82% of the 
thalassemic patients were HCV antibody positive and 
49% of them were viremic (HCV RNA positive). A 
study in Tanta University Hospital also reported that 
40% of the multi-transfused children had positive PCR 
for HCV [36].  
In our study, anti-HCV positive patients had 
higher mean serum ferritin, serum ALT, AST and GGT 
levels than the negative group (p = 0.015, 0.006, 
0.019 and 0.037 respectively). Also, HCV-PCR 
positive patients had higher mean serum ferritin and 
serum ALT than the negative group (p=0.001 and 
p=0.007 respectively). 
The findings of Ocak et al., (2006) [37] 
indicated that the patients who were anti-HCV positive 
had a significantly higher peak serum ALT level than 
anti-HCV-negative patients. Ameli et al., (2008) [3], 
found that serum iron was significantly higher in anti-
HCV positive patients compared to the negative 
group, and the same with the PCR positive group. 
Moreover, Omar et al., (2011) [8] stated that HCV 
antibody positivity was significantly higher with higher 
serum ferritin and higher liver transaminases and that 
PCR positivity was significantly related to patients’ 
serum ferritin level, which showed statistically 
significant positive correlation with liver 
transaminases.  
The results of this work showed that the level 
of serum ALT was highly significantly correlated with 
age of the patients and duration of blood transfusion 
(p=0.01 and 0.01 respectively).  
It was concluded that iron overload is a main 
leading cause of elevated liver enzymes and presence 
of HCV infection is significantly related to the 
increased iron overload. Although the risk of 
transfusion-associated hepatitis has been reduced, it 
is still high.  
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